Progestins' actions in the VTA to facilitate lordosis involve dopamine-like type 1 and 2 receptors

Pharmacology, Biochemistry, and Behavior
Cheryl A FryeKanako Sumida

Abstract

In the ventral tegmental area (VTA), 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP) facilitates lordosis. Whether this involves dopamine type 1 (D1) or dopamine type 2 (D2) receptors is of interest. Ovariectomized (ovx) rats with guide cannulae to the VTA were estradiol (E2) primed and pretested for lordosis. Rats were then infused with the D1 (Experiment 1) or D2 (Experiment 2) antagonists or agonists (0, 100, or 200 ng) to the VTA and were retested. After a second infusion of 3alpha,5alpha-THP (0, 100, or 200 ng) or vehicle, rats were tested 10, 60, and 120 min later. In Experiment 3, rats were administered a progestin receptor antagonist, RU38486, systemically or to the VTA 1 h prior to vehicle, SKF38393 and/or 3alpha,5alpha-THP infusions. 3alpha,5alpha-THP infusions increased lordosis over that seen with E2 priming. The D1 antagonist, SCH23390, attenuated 3alpha,5alpha-THP, but not E2-facilitated lordosis. The D1 agonist, SKF38393, augmented 3alpha,5alpha-THP, but not E2-facilitated lordosis. The D2 antagonist, sulpiride, had no significant effects on lordosis. The D2 agonist, quinpirole, prevented 3alpha,5alpha-THP-facilitated lordosis. RU38486 (subcutaneous) inhibited lordosis, whereas infusions to the VTA decreased ...Continue Reading

References

Aug 15, 1978·European Journal of Pharmacology·P E SetlerH L Saunders
Mar 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·D M WeinerM R Brann
Sep 9, 1986·European Journal of Pharmacology·A SidhuJ W Kebabian
Jan 1, 1987·Physiology & Behavior·I U VathyR J Barfield
Mar 1, 1974·Journal of Comparative and Physiological Psychology·J F Marshall, P Teitelbaum
Feb 1, 1984·Brain Research Bulletin·R L Meisel, D W Pfaff
Dec 3, 1984·Life Sciences·J C Stoof, J W Kebabian
Aug 1, 1983·Naunyn-Schmiedeberg's Archives of Pharmacology·K StarkeC Adelung
Jan 1, 1982·General Pharmacology·S E O'Connor, R A Brown
Dec 16, 1982·Nature·T C RainbowB S McEwen
May 5, 1980·Brain Research·N J MacLusky, B S McEwen
Jul 1, 1980·Brain Research Bulletin·J A MuntzR C Shults
Nov 25, 1993·Nature·D L Cameron, J T Williams
Jan 1, 1993·Neuroscience and Biobehavioral Reviews·S Ahlenius
Sep 1, 1993·Neuron·R RupprechtF Holsboer

❮ Previous
Next ❯

Citations

Aug 1, 2008·Animal : an International Journal of Animal Bioscience·B BeerdaR F Veerkamp
Mar 24, 2007·Reproduction : the Official Journal of the Society for the Study of Fertility·Cheryl A FryeMadeline E Rhodes
Feb 8, 2008·Pharmacology, Biochemistry, and Behavior·Vanya Quinones-JenabCheryl Frye
Jun 24, 2011·Journal of Neuroendocrinology·Cheryl Anne Frye
Jul 27, 2005·Hormones and Behavior·Alexander S KauffmanEmilie F Rissman
Aug 16, 2005·Pharmacology, Biochemistry, and Behavior·E TeodorovM M Bernardi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.